Paper Details

  1. Home
  2. Paper Details

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?

Author: JonesAlan M, JonesLauren

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigates the relationship between the polypharmacology of dipeptidyl-peptidase IV inhibitors (DPP4i) and their suspected adverse drug reaction (ADR) profiles using the UK's National MHRA Yellow Card Scheme and OpenPrescribing databases. The findings indicate that DPP4i show limited polypharmacology alongside low suspected ADR rates, with gastrointestinal and skin reactions being the most frequently reported ADRs.
Paper Details　
Original Abstract of the Article :
To interpret the relationship between the polypharmacology of dipeptidyl-peptidase IV inhibitors (DPP4i) and their suspected adverse drug reaction (ADR) profiles using a national registry. A retrospective investigation into the suspected ADR profile of four licensed DPP4i in the United Kingdom using...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720577/

データ提供：米国国立医学図書館（NLM）

Dipeptidyl-Peptidase IV Inhibitors: A Closer Look

The field of pharmacology is constantly exploring the intricacies of drug interactions and their potential effects on the body. This research investigates the suspected adverse drug reactions (ADRs) associated with dipeptidyl-peptidase IV inhibitors (DPP4i), a class of drugs used to treat type 2 diabetes. The authors utilize national registry data and experimental information to analyze the polypharmacology of DPP4i and their potential ADR profiles.

Unveiling the Complexities of Drug Interactions

This research sheds light on the complex interplay of drug interactions and their potential for ADRs. The authors reveal that DPP4i, while effective in treating type 2 diabetes, may have a range of potential ADRs, including gastrointestinal and skin reactions. This finding highlights the importance of considering the polypharmacology of drugs and their potential for off-target effects when prescribing medications.

Patient Safety: A Priority

This research underscores the importance of patient safety in drug development and prescription. The authors emphasize the need for continued monitoring of DPP4i to better understand their ADR profiles and ensure their safe and effective use. This understanding can help healthcare professionals make informed decisions about prescribing these medications and minimize the risk of ADRs for patients.

Dr.Camel's Conclusion

This research, like a camel navigating a vast and ever-changing desert landscape, reminds us of the complexities of drug interactions and the importance of patient safety. It highlights the need for continued research and vigilance in understanding the potential ADRs associated with medications, especially those with polypharmacological profiles. By approaching drug development and prescription with caution and careful consideration, we can ensure that patients receive the benefits of medication while minimizing the risks of unintended consequences.

Date :
  1. Date Completed 2022-12-08
  2. Date Revised 2023-09-18
Further Info :

Pubmed ID

36468400

DOI: Digital Object Identifier

PMC9720577

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.